Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRNL20240422032
- Term of Validity
- 23 April 2024 - 23 April 2025
- Company's Country
- Netherlands
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- SwitzerlandNetherlands
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Dutch company developed technology to generate superior mammalian cell lines that produce more biopharmaceutical protein per cell. The company is now tuning this technology to generate cell and gene therapy products more effectively. It is looking for Swiss partners for a EUREKA project: Cell and Gene Therapy Towards Clinical Practice in the Call Connecting the Dutch and Swiss Life Sciences Ecosystems. A research cooperation agreement or a technical cooperation agreement is foreseen.
- Full Description
-
Biopharmaceuticals are typically produced in cultured mammalian cells. The complex development and manufacturing method of these advanced therapy medicinal products results in their high pricing.
A Dutch biotech company has discovered and implemented genetic elements and developed highly cost-effective, production platforms for recombinant pharmaceutical proteins. Application of the technology increases production levels 2 to 3-fold compared to other systems commonly in use in the industry, resulting in improved efficiencies and lower production costs. Proof of value was demonstrated in different Chinese hamster ovary (CHO) cell types (e.g.: adherent and suspension CHO-K1, CHO-DG44, CHO-GS) with different selection markers (e.g.: blasticidin, puromycin, zeocin) for various proteins (e.g. monoclonal antibodies, biosimilars, difficult to express proteins). The technology is patented, generally applicable (cell types, selection markers, expressed proteins), and licensed to different pharmaceutical companies.
Currently the Dutch SME focuses on the development of its technology to solve the main issues of gene therapy: the difficulty to produce high amounts of viral particles and the limited payload of viral vectors.
The SME would like to establish a consortium within the EUREKA framework / Call for R&D Project Proposals Switzerland – the Netherlands: Cell and Gene Therapy Towards Clinical Practice and is looking for Swiss partners.
A research cooperation agreement is foreseen - Advantages and Innovations
- The Dutch SME focuses on the development of its technology to solve the main issues of gene therapy: the difficulty to produce high amounts of viral particles and the limited payload of viral vectors.
- Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR description
-
This represents a broad range of R&D topics. Partners from different application fields are invited, including partners developing gene therapy products, studying genes or proteins for gene therapy, developing mammalian cell-produced products, partners aiming to improve protein or viral vector production by process engineering, partners interested in developing and studying biopharmaceutical protein variants, partners carrying out studies relating to protein production yield or its related metabolic processes, etc.
Keywords:
- cell and gene therapy
- gene therapy
- ATMP (advanced therapy medicinal products)
- viral vectors
Partner Sought
- Expected Role of a Partner
-
- The company is seeking collaboration with other companies (SME’s, large companies), institutes and academia related to its expertise on producing viral vectors and/or proteins for development and research.
- This represents a broad range of R&D topics. Partners from different application fields are invited, including partners developing gene therapy products, studying genes or proteins for gene therapy, developing mammalian cell-produced products, partners aiming to improve protein or viral vector production by process engineering, partners interested in developing and studying biopharmaceutical protein variants, partners carrying out studies relating to protein production yield or its related metabolic processes, etc.
- The Dutch SME is seeking both technical as well as research cooperations. It is interested in different programs, like Eurostars and EIC, as well as participation in consortia created to address topic-specific Horizon Europe calls. - Type and Size of Partner
- OtherR&D InstitutionUniversitySME 11-49SME 50 - 249SME <=10Big company
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Eureka
- Call title and identifier
-
EUREKA framework / Call for R&D Project Proposals Switzerland – the Netherlands: Cell and Gene Therapy Towards Clinical Practice
- Submission and evaluation scheme
-
Call opening on 12 February 2024
Submission Project Outline by 5 June 2024
Submission of Full project proposal by 25 September 2024
Funding decisions communicated November 2024 Project start at latest by 1 March 2025 - Anticipated project budget
-
to be decided
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
100
- Web link to the call
- https://eurekanetwork.org/
- Project title and acronym
-
EUREKA framework / Call for R&D Project Proposals Switzerland – the Netherlands: Cell and Gene Therapy Towards Clinical Practice
Submission Project Outline by 5 June 2024
Submission of Full project proposal by 25 September 2024
Funding decisions communicated November 2024 Project start at latest by 1 March 2025
Dissemination
- Technology keywords
- 06001002 - Clinical Research, Trials06002002 - Cellular and Molecular Biology06002004 - Protein Engineering06001009 - Gene - DNA Therapy06002005 - Genetic Engineering
- Market keywords
- 04002 - Monoclonal Antibodies and Hybridomas04004 - Other Genetic Engineering04006 - Cellular and Molecular Biology
- Sector Groups Involved
- HealthEnergy-Intensive Industries
- Targeted countries
- SwitzerlandNetherlands